title: EOL-1 cells, 0.5 M imatinib 24h
design: The following cell lines were treated (or not) with the effective TKI: K562 1 M imatinib 24h; EOL-1 0.5 M imatinib 24h; KG1a 0.1 M Ponatinib 48h; Mv4-11 0.01 M quizartinib 24h; MOLM-13 0.01 M quizartinib 24h; KAS-1 0.1 M quizartinib 24h. RNA was extracted and sent to Macrogen for small RNA-sequencing. Multiplexed samples libraries (TruSeq, Illumina) were prepared and sequenced within the same flow cell (HiSeq 2000).